Background Typhoid causes significant mortality among young children in resource-limited
settings. Conjugate typhoid vaccines could significantly reduce typhoid-related child deaths …

Background The Vi-diphtheria toxoid typhoid conjugate vaccine (Vi-DT) has shown
promising results in preventing typhoid fever in children under 2 years of age. However, a …

Background Typhoid fever remains an important public health problem in developing
countries and is endemic in many parts of Asia and Africa where the incidence of disease …

Background Typhoid fever caused by Salmonella enteric serovar Typhi (S. Typhi) is a
common cause of morbidity in the world. In 2017, 14.3 million cases of Typhoid and …

Background Typhoid fever caused by multidrug-resistant H58 Salmonella Typhi is an
increasing public health threat in sub-Saharan Africa. Methods We conducted a phase 3 …

Background Typhoid fever remains a major public health problem in low-and middle-income
countries where children aged 2–14 years bear the greatest burden. Vi polysaccharide is …

Objective To compare the immunogenicity and safety of an investigational typhoid Vi
conjugate vaccine (Test TCV) with a marketed typhoid Vi conjugate vaccine (Comparator …

Background Typhoid fever remains a major public health problem globally. While new Vi
conjugate vaccines hold promise for averting disease, the optimal programmatic delivery …

Introduction There is a high global incidence of typhoid fever, with an annual mortality rate of
200,000 deaths. Typhoid fever also affects younger children, particularly in resource-limited …

Background: Randomised controlled trials of typhoid conjugate vaccines among children in
Africa and Asia demonstrate high short-term efficacy. Data on durability of protection beyond …